g jollibee
Hisense's HT Saturn speakers feature wireless Dolby Atmos and room calibrationMLB rumors: Chapman would make temporary change if Giants sign KimSenegal PM seeks to repeal contested amnesty law
Aaron Judge won't be bothered if Juan Soto gets bigger contract from Yankees than his $360M deal
Sirius XM Holdings Inc. stock underperforms Thursday when compared to competitorsIntegration of industry, govt platforms can improve logistics: Piyush Goyal
What a year! Tour operators share their standout moments from 2024
JSW group in talks with Chinese biggies to charge up its EV Drive
Some Dems frustrated
Donald Trump shared a strange post on Truth Social revealing that Microsoft co-founder Bill Gates asked to visit him at Mar-a-Lago, with many believing it was meant to be a private message. Since Trump's victory in November 2024, several tech executives have sought meetings with the president-elect at his Mar-a-Lago estate, aiming to discuss issues such as job creation, manufacturing and policy concerns. On Friday, December 29, Trump shared a Truth Social post where he mentioned that Bill Gates had requested to meet with him at Mar-a-Lago, CNN reported. The visit in question would be his second in-person meeting with Trump since 2016. "Where are you? When are you coming to the "Center of the Universe," Mar-a-Lago. Bill Gates asked to come, tonight. We miss you and x! New Year's Eve is going to be AMAZING!!! DJT," Trump wrote . The meeting's outcome is still uncertain, as Gates has not publicly confirmed plans to visit. Originally published by Latin Times
Chicopee police hoping to tap AI for enhanced crime responseFormer Prime Minister Manmohan Singh had a special bond with Visakhapatnam and participated in quite a few programmes in the city, including the laying of foundation stone for the expansion of the Visakhapatnam Steel Plant (VSP). He was also instrumental in the expansion of Hindustan Petroleum Corporation Limited (HPCL). There was an air of festivity at the VSP during the visit of Dr. Singh on May 20, 2006. “He laid the foundation stone for expansion of the VSP, besides presenting the PM’s trophy for being the Best Integrated Steel Plant from the same platform. The then CMD, Y. Siva Sagar Rao, received the trophy from Dr. Singh,” recalled a VSP official on Friday. The then Chief Minister, Y.S. Rajasekhara Reddy, the then Union Minister of Steel, Ram Vilas Paswan, and the then MP, T. Subbarami Reddy, were among those present on the occasion. The stone was laid for expansion of the steel plant capacity from 3 million tonnes to 6.3 million tonnes. “Dr. Singh was instrumental in the merger of Hindustan Shipyard Limited (HSL), which was then in losses, with the Defence sector and the Bharat Heavy Plate and Vessels Limited (BHPV) with the Bharat Heavy Electricals Limited (BHEL). He had announced that another shipyard would be allotted to Andhra Pradesh. He had participated in the inaugural of the Gangavaram Port and played a key role in the setting up of the Naval Alternate Operating Base (NAOB) at Rambilli in Visakhapatnam district,” Koyya Prasada Reddy, former Chairman of AP Technology Services (APTS), told The Hindu . Dr. Singh, who was the chief guest at the five-day Indian Science Congress, organised by the Indian Science Congress Association (ISCA) at Andhra University in January 2008, had announced a new scheme – INSPIRE – to attract talent. Dr. Singh had launched INS Arihant, the nuclear-powered submarine, which was built at the Hindustan Shipyard Limited (HSL), on July 26, 2009, the anniversary of ‘Kargil Vijay Diwas’, organised to mark the victory of India over Pakistan in the Kargil War. He had asked his wife Gursharan Kaur to break the coconut to mark the launch of the submarine. Meanwhile, leaders of political parties and others from various walks of life condoled the demise of Dr. Singh. YSRCP MLC Botcha Satyanarayana paid tributes to Dr. Singh in the city. Former Minister Gudivada Amarnath garlanded the portrait of Dr. Singh at the party office. Rajya Sabha member Golla Babu Rao, MLC Varudu Kalyani, party leaders T. Vijay Kumar, T. Nagireddy and Chintalapudi Venkataramaiah paid tributes to the departed leader. Published - December 28, 2024 02:40 am IST Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp Reddit Andhra Pradesh / politics / Indian National CongressResettlement of TTP militants: Nation, army paying in blood for one man's errorSignificant economic progress made in last nine months: Marriyum
Fianna Fail and Fine Gael eye independent TDs as option to secure Dail majorityNone
PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications. Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq. Vincerx is also implementing additional streamlining and cost-control measures, including a workforce reduction, as it pursues due diligence and transaction-related work. As part of this workforce reduction, Dr. Ahmed Hamdy, Chairman and Chief Executive Officer (CEO), has stepped down as CEO but will remain as Chairman. Dr. Raquel Izumi has stepped down as President and Chief Operations Officer and taken over as Acting CEO in a consulting capacity. Alexander Seelenberger has stepped down as Chief Financial Officer, and Kevin Hass, the Company’s Vice President and Controller, has taken over as Acting Chief Financial Officer. Mr. Seelenberger has agreed to provide ongoing assistance in a consulting capacity to assist the Company as it pursues its strategic efforts. “This strategic transaction highlights Vincerx’s commitment to develop ADCs with improved safety profiles that allow patients to thrive on—rather than endure—their cancer therapies,” said Raquel Izumi, Ph.D., Acting Chief Executive Officer. “Oqory’s anti-TROP2 ADC has shown favorable efficacy and safety in the clinic. Among approximately 150 treated patients, results include an 83% overall response rate and 100% disease control rate in first-line triple-negative breast cancer (TNBC; n=30). Unlike other TROP2 ADCs in Phase 3, no cases of interstitial lung disease or Grade 3 and above stomatitis have been reported. Oqory’s Phase 3 studies of OQY-3258 are ongoing to confirm these promising findings.” About OQY-3258 (also known as ESG401) OQY-3258 is Oqory’s anti-TROP2 ADC with an optimized enzyme-dependent linker technology and an SN-38 payload with established efficacy and manageable side effect profile. OQY-3258 has completed Phase 1/2 development in over 150 patients with solid tumors, including metastatic HR+/HER2- and triple-negative breast cancer. OQY-3258 has shown efficacy in these patients, including reduction of brain metastasis and responses in heavily pretreated patients. To date, OQY-3258 has exhibited a differentiated safety profile vs. Trodelvy and other TROP2 ADCs in Phase 3 development. Notably, no interstitial lung disease or ocular surface events have been observed. Gastrointestinal effects have been mild and mainly Grade 1/2. Neutropenia and leukopenia have been the major AEs, which were manageable and did not result in discontinuation of study drug. OQY-3258 is being evaluated in a Phase 3 study as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer ( NCT06732323 ) and in a Phase 3 study in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer ( NCT06383767 ). About Oqory, Inc. Oqory, Inc. is an innovator in the field of ADCs with expertise in advancing targeted cancer therapies. The Company’s pipeline includes multiple ADC programs, with two currently in clinical development and several next-generation ADCs in preclinical stages. These programs are designed to address critical unmet needs in indications such as breast cancer, non-small cell lung cancer, small cell lung cancer, multiple myeloma, and other metastatic solid tumors. Powered by a proprietary ADC platform, Oqory is delivering therapies that have demonstrated promising efficacy and safety paving the way for improved patient outcomes. About Vincerx Pharma, Inc. Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx’s pipeline consists of a next-generation ADC, VIP943, currently in Phase 1; a small molecule drug conjugate, VIP236, which has completed its Phase 1 study; a CDK9 inhibitor, enitociclib, which has completed a Phase 1 monotherapy study; a preclinical ADC, VIP924; and VersAptxTM, a versatile, next-generation bioconjugation platform. Vincerx is based in Palo Alto, California, and has a research subsidiary in Monheim, Germany. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “suggest,” “seek,” “intend,” “plan,” “goal,” “potential,” “on-target,” “on track,” “project,” “estimate,” “anticipate,” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, the entry into a definitive merger agreement; the anticipated terms and closing of the merger, the $20 million equity investment, and the amount and timing of the interim financing; the expected ownership structure and value to Vincerx stockholders upon closing of the merger; the anticipated benefits of a merger transaction; and the clinical results of Oqory’s product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations, and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside Vincerx’s control. Actual results, conditions, and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions, and events to differ materially from those indicated in the forward-looking statements include, but are not limited to, Vincerx’s capital requirements, availability and sufficiency of capital, and cash runway; the ability of the parties to enter into a definitive merger agreement and the final terms thereof; the parties’ ability to satisfy the conditions precedent to the merger, including stockholder approval; the closing of the merger; the risk that any definitive agreement is terminated after it is entered into but before consummation of any proposed merger;; Vincerx’s reliance on receipt of interim funding; market acceptance of the combined company; risks associated with clinical development of the Vincerx and Oqory product candidates; general economic, financial, legal, political, and business conditions; and the risks and uncertainties set forth in Vincerx’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and subsequent reports filed with the Securities and Exchange Commission by Vincerx. Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements. Vincerx and the Vincerx logo are trademarks of Vincerx. This press release also contains trademarks and trade names that are the property of their respective owners. Contacts: Gabriela Jairala Vincerx Pharma, Inc. gabriela.jairala@vincerx.com Totyana Simien Inizio Evoke Comms totyana.simien@inizioevoke.comRiyadh Metro Successfully Delivered by Parsons-Led Joint VentureWhen does Black Ops 6 season 1 Reloaded release?
ZDNET's product of the year: Oura Ring 4 bested Samsung, Apple, and others in 2024
R emember the old story, perhaps apocryphal, that upon first encountering cameras, some native Americans refused to pose for photographs, fearing their souls might be stolen? The other day I looked at social media and knew how they felt. Someone had recorded a film of me locked in passionate embrace with an attractive woman. With a feeling of queasy surreality, I watched myself swoop in for a kiss. It was me, all right — my face, my hair and even my shirt. Except it wasn’t. For this was a deepfake: a digitally generated film of something that never took place, designed with the help of AI to look convincing. And it was on the internet, where others could see it too. In a promo released this week, the Instagram head Adam Mosseri, sporting a number of rapidly changing outfits, against multiple backdrops, described how the platform would soon be introducing AI tools “to help realise your ideas” and “do anything you want with your videos”. Emphasising the point, in one frame a hyperrealistic hippo lounged about in a swimming pool behind him.